Comparative Pharmacology
Head-to-head clinical analysis: CERADON versus CORTENEMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERADON versus CORTENEMA.
CERADON vs CORTENEMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly enhances cognitive function by modulating cholinergic and dopaminergic pathways.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
500 mg orally every 8 hours; for severe infections, 750 mg every 12 hours or 1 g every 8 hours.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
None Documented
None Documented
3-5 hours in healthy adults; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20 hours in severe impairment (CrCl <30 mL/min).
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total: >90% eliminated within 48 hours.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Category C
Category C
Corticosteroid
Corticosteroid